About Actelion
Actelion: Transforming Pulmonary Hypertension into a Manageable Condition
Actelion is a leading biopharmaceutical company that specializes in the development and commercialization of innovative drugs for the treatment of pulmonary hypertension (PH) and other rare diseases. The company was founded in 1997 by five scientists who shared a common vision to improve the lives of patients suffering from PH, a life-threatening condition that affects the lungs and heart.
Our vision is to transform PH into a long-term, manageable condition, so that patients can live a normal life. We are committed to developing innovative therapies that address unmet medical needs and improve patient outcomes. Our research efforts are focused on understanding the underlying mechanisms of PH and developing targeted therapies that can slow or reverse disease progression.
At Actelion, we believe in putting patients first. We work closely with patient advocacy groups to ensure that our research efforts are aligned with patient needs. We also collaborate with healthcare professionals to develop educational programs and resources for patients living with PH.
Our portfolio of products includes several approved therapies for the treatment of PH, including Tracleer® (bosentan), Opsumit® (macitentan), Uptravi® (selexipag), Veletri® (epoprostenol) and Ventavis® (iloprost). These drugs have been shown to improve exercise capacity, reduce hospitalizations, and increase survival rates in patients with PH.
In addition to our approved products, we have several promising pipeline candidates in various stages of development. These include selexipag extended-release tablets for pulmonary arterial hypertension (PAH), cadazolid for Clostridium difficile-associated diarrhea (CDAD), ponesimod for multiple sclerosis (MS) and ACT-132577 for resistant hypertension.
We are committed to advancing scientific knowledge through clinical trials and collaborations with academic institutions around the world. Our research efforts have led to numerous publications in peer-reviewed journals, as well as presentations at major scientific conferences.
At Actelion, we believe in sustainability as an integral part of our business strategy. We strive to minimize our environmental impact by reducing energy consumption, waste generation, water usage and greenhouse gas emissions across all aspects of our operations.
In conclusion,
Actelion is dedicated towards transforming pulmonary hypertension into a manageable condition so that people suffering from this disease can lead normal lives like others do without any hindrance or fear about their health conditions affecting their daily activities or lifespan negatively.
With its commitment towards innovation & research alongwith its focus on putting patients first has made it one among leading biopharmaceutical companies globally.
Its portfolio includes several approved therapies which have been proven effective against this disease while it continues working on new pipeline candidates which hold promise against other rare diseases too.
The company's commitment towards sustainability makes it stand out among others while its collaborations & partnerships across academic institutions worldwide further strengthens its position as an industry leader.
Overall Actelion's dedication towards improving human health & quality-of-life makes it an ideal choice when looking out for reliable pharmaceutical companies working towards betterment & welfare of society at large!